BRCA1 & BRCA2: Knowing Your Risk

For women, men, and families. The conversations worth having. The next steps worth understanding.

By Max · Prepared November 14, 2026 · General U.S. guidance

Start here · Women · Men · Pancreas · Testing limits · Appointment checklist

Why I am writing this

My wife, Nina, had a harmful BRCA1 mutation. I walked beside her through ovarian cancer. She died on May 25, 2025.

These are deeply personal words for me. They are also the reason I want this page to be useful. When someone hears “BRCA1” or “BRCA2,” I want them to have somewhere to begin: the right report, the right specialist, and questions they can bring into the room.

I share this as Nina’s husband and caregiver. I am not a clinician. Our experience with BRCA1 is personal; the information below comes from the medical sources linked throughout this page.

Knowing your risk can give you a chance to make a plan.

A positive inherited BRCA result is not a cancer diagnosis. It indicates increased risk; it cannot predict whether or when cancer will occur. This page is general awareness, not individual medical advice. Plans depend on age, family history, prior cancer, anatomy, previous surgery, and personal priorities. Guidelines change; confirm current recommendations with your care team.1

Begin with genetic counseling

Everyone has BRCA1 and BRCA2 genes. Certain harmful changes affect DNA repair and increase cancer risk. Get the actual laboratory report and ask a genetic counselor what it means.1

  • Pathogenic or likely pathogenic: a harmful finding that can guide risk management.
  • Variant of uncertain significance (VUS): not a confirmed harmful mutation. It should not by itself drive preventive surgery; care follows personal and family history while classification is monitored.
  • Negative: interpretation depends on whether a known family variant was specifically tested and on the remaining family history.

Inherited testing usually uses blood or saliva. A mutation found only in a tumor may need separate germline testing. Some consumer tests miss harmful variants. Ask whether targeted testing for a known family change or a broader panel is appropriate.1

Your father’s side counts too

Women and men can inherit and pass on either mutation. Each child of a carrier has a 50% chance of inheriting it—not a 50% certainty of cancer. Share the exact report with adult blood relatives and ask about family testing. BRCA testing is generally deferred until adulthood.2, 3

Breast and ovarian health need separate plans

A high-risk breast clinic and a gynecologic oncologist or hereditary gynecologic cancer specialist can help coordinate care. The following ages are discussion benchmarks for confirmed harmful inherited variants, not a personal prescription.4

CareBRCA1BRCA2
Breast imagingAnnual breast MRI with contrast generally from 25; add annual mammography at 30. Both are usually continued through 75, then individualized. Clinical breast exams every 6–12 months from 25.
Ovarian / fallopian tube risk reductionRemoval of both ovaries and fallopian tubes generally at 35–40, after childbearing.Generally at 40–45, after childbearing.
Common starting points to discuss

Source: Basser Center. Family history and individual circumstances can change timing.4

Screening seeks earlier detection; risk reduction aims to lower the chance of cancer. Discuss bilateral risk-reducing mastectomy, reconstruction, and the benefits and harms of surveillance. Surgery substantially reduces breast cancer risk, but cannot eliminate it.5

Before ovarian surgery, discuss fertility preservation, menopause, sexual health, bone and heart health, and whether hormone therapy is appropriate. Removing only the fallopian tubes with later ovarian removal is being studied; it is not an established equivalent to timely removal of both. A residual risk of primary peritoneal cancer remains after surgery.1, 5

Ask whether risk-reducing medication or oral contraception has a role for you. Benefits and harms differ, and these do not replace the ovarian surgery discussion.5, 6

BRCA is part of men’s health too

Men need care for their own risk, as well as awareness of what a result means for their children. BRCA2 is especially important for male breast and prostate cancer risk.7

  • Breast: from 35, discuss breast self-exam training and an annual clinical exam for either gene. Ask whether mammography is appropriate, often considered from 50 or earlier according to family history, especially with BRCA2.
  • Prostate: from 40, annual PSA-based screening is recommended for BRCA2 and considered for BRCA1. A clinician may include a digital rectal exam and discuss false positives and further testing.
  • Pancreas: review eligibility for specialist surveillance as described below.

Report a new breast lump, nipple discharge, or skin or nipple changes promptly, rather than waiting for a scheduled check.7

These women’s and men’s sections follow the language used by the sources. For transgender and nonbinary people, screening should reflect organs and tissue present, hormone exposure, prior surgery, and individual history.

Ask specifically about the pancreas

Pancreatic surveillance is a separate specialist conversation. Under the current NCCN approach, BRCA2 carriers can consider it regardless of family history. For BRCA1, this approach generally requires a first- or second-degree relative with pancreatic cancer on the relevant side of the family. Other professional guidance differs.8

If surveillance is chosen, it commonly begins at 50, or 10 years before the youngest pancreatic cancer diagnosis in the family, whichever comes first. An experienced high-volume center may use annual MRI/MRCP and/or endoscopic ultrasound (EUS). Discuss uncertain benefit, false positives, and procedure risks. This is not a routine blood-test screening program.8, 6

Know what a test can—and cannot—tell you

A normal Pap test does not mean your ovaries have been screened. Pap and HPV testing address cervical cancer risk. They do not screen for ovarian or pancreatic cancer. Continue cervical screening when appropriate, but do not confuse its purpose.9

There is no proven effective routine ovarian screening for people without symptoms. CA-125 and transvaginal ultrasound can miss early disease and have not been shown to improve survival through screening. They may help investigate symptoms or be used selectively by specialists; normal results cannot replace a risk-reduction plan.6, 9

Symptoms deserve their own appointment

New, persistent bloating, pelvic or abdominal pain, feeling full unusually quickly, or changes in urination or bowel habits deserve evaluation. CDC advises seeing a doctor when these changes last two weeks; contact your team sooner if concerned. Unusual vaginal bleeding needs prompt assessment. Symptoms often have other causes, but a previous normal test should not stop a new evaluation.10

Your next appointment

Bring the report, cancer diagnoses and ages from both sides of the family, previous screening results, and your questions. Ask for a written plan and the name of the clinician coordinating it.

  • What exactly does my result mean? Is the finding inherited and confirmed?
  • Which specialists do I need, and which appointments should I book now?
  • Which screening tests apply to me, at what age, and how often?
  • What can reduce my risk? What are the benefits, limitations, and timing?
  • How would surgery affect fertility, menopause, sexual health, and daily life?
  • Do I qualify for pancreatic surveillance or a clinical trial?
  • Which relatives should seek counseling, and how can I share the report?
  • What symptoms should prompt a call, and when will we review this plan?

Use your browser’s Print command to bring this guide to your appointment. No health information is collected by this guide.

What I hope you take with you

I cannot tell you what would have changed Nina’s story. I can tell you why I care about the next person who receives a genetic result and wonders what to do with it.

You deserve time to understand it. You deserve answers in language you can follow. And you deserve a plan made with people who understand hereditary cancer.

If this page helps you begin that conversation, it has a place in Nina’s memory.

— Max

Read Nina’s story: Before the Goodbye